The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much ...
A prospective, multicenter cancer clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) has validated an ...
A novel triple receptor agonist conferred weight loss of up to 28.7% at 68 weeks and reductions in pain for adults with ...
A study published in the Journal of Clinical Oncology confirms that one of the first Food and Drug Administration-approved CAR-T cell therapies offers long-term survival and potential cures for adult ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback